Rajiv Agrawal, PhD

Associate Director, Pharmacology

Rajiv Agrawal, Ph.D., joins the team to accelerate the pharmacology efforts of Psychedelics-inspired medicine in neuropsychiatric disorders.

Dr. Agrawal joins Delix from Frequency Therapeutics where he served as the in vitro lead for the MS group to identify novel phenotypic screen and functional assays for small molecules in remyelination.  Prior to that, Dr. Agrawal has held positions at Sanofi with focus on developing on pharmacological models in the same area. Dr. Agrawal also brings experience in the area of peripheral immune diseases from his time at Glenmark Pharmaceuticals (India).

Dr. Agrawal is neuroscientist by training having received his Ph.D. in Pharmacology and Neuroscience from Texas Tech University.  He attained his Bachelor's degree in Pharmaceutical Sciences from India.